Sample Page
Author:
Disc Medicine Inc
Posted Date:
June 12, 2026
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Disc Medicine Inc
June 12, 2026
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Disc Medicine Inc
June 9, 2026
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine Inc
June 2, 2026
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Disc Medicine Inc
June 1, 2026
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Disc Medicine Inc
May 12, 2026
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine Inc
May 11, 2026
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Disc Medicine Inc
May 7, 2026
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine Inc
April 21, 2026
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine Inc
February 24, 2026
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Disc Medicine Inc
February 13, 2026
